GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of why does nobody talk about mechanism — 50 comments in the full submission. View in context.
1.5k
c/glp1science·submitted 10 months ago by u/incretin_ivy

why does nobody talk about mechanism

Questionbranch of 7 comments

why does nobody talk about mechanism, and I want the answer with the reasoning attached rather than just the conclusion. Was completely wrong about the gastric emptying story in a thread here two years ago. Someone corrected me with a citation and I have not made that mistake since. Receptor expression in a tissue is…

Read the full submission and all 50 comments →

This branch

7 comments, started 10 months ago
u/gastric_emptying_gMOD318 points·10 months ago

Speculation is welcome here if it is labelled. This one has been relabelled rather than removed.

replysharereportpermalink
u/incretin_ivyOPpharmacology-34 points·10 months ago

Is there any human data on that mechanism yet?

replysharereportpermalink
u/greta_lokken1 point·10 months ago

receptor agonism is not the same as receptor activation in every tissue

replysharereportpermalink
u/lurker_for_years1 point·10 months ago

receptor agonism is not the same as receptor activation in every tissue

Adding the caveat the paper itself makes in its limitations section, which is stronger than anything in this thread.

replysharereportpermalink
u/incretin_ivyOPpharmacology0 points·10 months ago

Small fix — it slows gastric emptying, it does not halt it, and the distinction matters for the mechanism you are proposing.

replysharereportpermalink
u/anya_salgado1 point·10 months ago

Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.

replysharereportpermalink
[deleted]1 point·10 months ago

[deleted]

replysharereportpermalink

← back to the whole thread

About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/glp1science
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/trialwatch_theou/gastric_emptying_gu/sig_figs_sam
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →